Oncodesign in up to 130 million-euro deal with Sanofi

Oncodesign, a Dijon, France-based drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with French drug major Sanofi (Euronext: SAN) to apply exclusively Oncodesign’s Nanocyclix technology to several Sanofi kinase target programs.

Under the terms of the agreement, Oncodesign will exclusively apply its Nanocyclix technology platform in multiple undisclosed Sanofi kinase programs for a number of therapeutic applications over a period of four years. Oncodesign is entitled to an undisclosed technology access fee and discovery, development, regulatory and commercial milestone payments totaling up to 130 million euros ($164 million) and low single digit royalties on net sales.

This is the second major deal this year for Oncodesign, which previously entered an accord with France’s Ipsen worth a potential 115 million euros to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's disease and for potential additional uses in other therapeutic areas (The Pharma Letter January 5).